Bayer Aktiengesellschaft (BAYN) Earnings Call Transcript & Summary
March 5, 2025
Earnings Call Speaker Segments
Jost Reinhard
executiveGood afternoon, everyone — and good morning to those joining us — and welcome to the conference call where we'll go over the fourth quarter and the full-year results for 2024. First up, Bill will give his take on how our business has been developing, the progress achieved in our transformation, and what lies ahead for us. After that, Wolfgang will walk us through an overview of our financial performance in 2024, together with the outlook for 2025. Following them, our divisional heads will speak, going into detail on how their businesses performed last year, as well as their future ambitions and action plans. As usual, we'll wrap up the presentations with the Q&A sessions. Before we get started, please take note of the cautionary language in our Safe Harbor statement — and with that, Bill, over to you.
Bill Anderson
executiveThanks, Jost. And thank you, everyone, for being here. I'll begin with how we did in 2024 and what we see for 2025, then I'll lay out what you should expect from us during this year as our turnaround keeps moving forward. Let's begin with 2024. We revised our full-year EBITDA guidance back in November of last year. As a group, our results came in line with that updated outlook. In fact, EBITDA before special items ended up just shy of our initial target, and the credit goes to our Pharmaceuticals division, which delivered above expectations and offset weakness elsewhere. On cash flow, we came in a touch above our guidance, and we brought net debt down to EUR 32.6 billion. It's clear there is still work ahead of us. We have three great businesses with attractive long-term prospects. We expect them to compete at the forefront of their fields. Whenever that's not the case, we're going to take action. And that brings me to 2025. So it's the second year in our turnaround. And as we indicated in November, we expect it to be the most difficult in terms of financial performance, with net sales roughly in line with and earnings and cash flow behind prior year. Let's look at it business by business.
Bill Anderson
executiveFor Pharmaceuticals, we expect net sales to come in a bit under 2024. We anticipate modest margin erosion as the Xarelto patent expiry hits harder. In Consumer Health, our goal is growth matching the market, along with an EBITDA margin before special items within the same range as 2024. For Crop Science, we foresee a gradual market rebound, though regulatory hurdles and crop protection pricing will keep pressure on earnings, holding margins where they are now. These headwinds grew worse for our Crop Science business in 2024. Our results make that clear, and we expect the effects to carry into 2025. As you'll see, we've made Crop Science profitability a fifth focus area on our agenda. See that as an early signal of our commitment to improving. We're 1 year into a multi-year effort. During 2024, we launched a comprehensive transformation aimed at Bayer's most pressing challenges and at positioning the company for a better future. We expect an improved trajectory to begin in 2026, and later today you'll hear why we're optimistic. Still, reaching those opportunities requires navigating a tight 2025. It's a pivotal year for our turnaround. From managing litigation to generating cash and paying down debt, to running each of our businesses, we have a big, big year ahead.
Bill Anderson
executiveSo here's what to expect. To start with, on Pharmaceuticals, growth, and pipeline: our two flagship launches, Nubeqa and KERENDIA, reached a combined EUR 2 billion in sales last year. During 2025, we intend to increase cumulative sales for those two medicines to over EUR 2.5 billion, and two additional pharmaceutical launches are coming in 2025 — Beyonttra arriving in European markets beginning in April, and Elinzanetant anticipated in the U.S. during the second half of the year. We're rejuvenating the pipeline as well. In 2024, nine positive phase III trials were successfully completed, and over the past 18 months we've moved more than 20 clinical programs forward. We have strong confidence that our Pharma business will get back to growth starting in 2027 and will expand margins beginning in 2028. Moving on to litigation. In 2024, we were active in the courtroom, with lawmakers, and in communicating important facts to the public. Our multi-pronged strategy continues in 2025, including collaborating with the new administration, with the U.S. Congress, and with lawmakers across a number of states to deliver important regulatory clarity regarding the future of farming and crop protection. I've personally devoted a great deal of my time to this effort so far this year and obviously in 2024 as well.
Bill Anderson
executiveDuring this calendar year, we're going to try hard to take major steps toward containment. We aim to build on the significant progress made in 2024 in the appellate courts, and we expect to hear from the Washington State Supreme Court on PCBs, and we hope to move the labeling preemption topic forward to the U.S. Supreme Court as well. All of these are milestones on the way to our objective of substantially containing litigation by the end of 2026, and we reaffirm that goal today. Moving on to cash and deleveraging. A year ago, we made a commitment to put debt reduction first, and you can see that reflected in our 2024 numbers. For 2025, that commitment remains unchanged. Wolfgang will talk more about that later. Next, our additional focus area: Crop Science profitability. Outstanding assets reside within our Crop Science business, exceptional global platforms, including a highly profitable Seeds business, an industry-leading pipeline, and excellent people. However, our business faces cost pressures in ways that are both unique to our business and common across our industry, with the biggest factor being generic pricing pressure on our leading crop protection business. This has eroded earnings, particularly in crop protection, that a leading business simply cannot accept. Our Crop Science team has launched a comprehensive plan to tackle earnings headwinds.
Bill Anderson
executiveThe main point I want to stress is that we're on a course to generate additional growth and to boost our margins substantially via actions within our own control. Our full board of management is behind these initiatives. Our aim is growth that outpaces the market, and that covers over EUR 3.5 billion in added sales stemming from innovation plus lifting the EBITDA margin into the mid-20s by 2029. Rodrigo will go into greater detail on the steps we're taking to reach that. The Crop Science program is additional as well and will work alongside our operating model, Dynamic Shared Ownership, which is advancing quickly. We switched the system on throughout the organization last year, cutting roughly 7,000 positions in 2024. If you trace back to when our work on this began, in the summer of 2023, and then follow it all the way through January of this year, that's in fact 10,000 positions removed, the majority of them management roles. So we anticipate further reductions as the new setup takes hold. During 2025, we're concentrating on making sure every team and network of teams gets proficient in the new ways of working, with people and resources moving toward the highest-priority outcomes, which delivers greater speed and impact, along with the savings we've committed to.
Bill Anderson
executiveFor 2025, we've got EUR 800 million in savings planned. I'm confident that by 2026 we won't just hit the EUR 2 billion we've committed to in savings — more importantly, we're going to see wider performance benefits. To wrap up, 2025 is the year when you'll see Team Bayer focused squarely on the biggest things in front of the company, with a clear commitment to deliver. So thank you for your attention, and Wolfgang, over to you.
Wolfgang Nickl
executiveThanks, Bill. Before I turn to the 2025 outlook, I want to provide a bit more detail on how the group performed in 2024. For 2024, net sales rose modestly, up 1% compared with the prior year on a currency- and portfolio-adjusted basis. That matches the guidance we gave at the Capital Markets Day in March. Gains in Pharmaceuticals and Consumer Health more than made up for the decline in Crop Science. EBITDA before special items reached EUR 10.1 billion, which is 14%, or roughly EUR 1.6 billion, under the prior year, yet it was in line with the revised guidance we covered in November. The year-on-year difference comes mainly from weaker Crop Science and Reconciliation results, along with negative foreign currency effects. I want to point out that on Reconciliation, we actually did better than the assumptions in our guidance. We were lapping a positive EBITDA before special items in 2023. On foreign exchange, we absorbed substantial headwinds on both our top and bottom line. At group level, net sales took a hit of more than EUR 1.3 billion, and EBITDA before special items was affected by nearly EUR 600 million. For our group EBITDA margin, currencies had a dilutive impact of 60 basis points.
Wolfgang Nickl
executiveBecause of where our sales are located geographically and where our cost base sits, Pharma margin faced a substantial headwind of 190 basis points, while Crop Science and Consumer Health both enjoyed margin tailwinds. Regarding short-term incentive provisions, we recorded roughly EUR 600 million in additional expenses relative to the prior year, and that was mainly caused by how our Pharma division performed. In connection with our dynamic shared ownership model, we booked around EUR 500 million of total organizational savings at group level during 2024, which partly offset the higher STI and inflation in 2024. The core financial result matched the prior year, since greater interest expenses were offset by reduced hedging costs compared with 2023. For the full year, our core tax rate was 25.4%. That rise relative to 2023 stemmed mostly from the devaluation of deferred tax assets in the United States. As a result, core earnings per share of EUR 5.05 fell short of the prior year, pulled down by the decrease in EBITDA before special items. The FX headwind affecting core earnings per share amounted to roughly EUR 0.40. Reported earnings per share were EUR -2.60, as shown in the appendix. The gap between that and core earnings per share comes mainly from regular amortization plus non-cash relevant impairment losses on intangibles of approximately EUR 4.2 billion.
Wolfgang Nickl
executiveThat was mainly due to the Crop Science impairment already recorded in Q3, along with impairment losses tied to higher development costs and regulatory uncertainties in Pharma booked in Q4. On top of that, special items in EBITDA came to roughly EUR 1.4 billion, driven largely by restructuring. Free cash flow landed above our guidance, at EUR 3.1 billion versus EUR 1.3 billion a year earlier. The increase compared with last year stems chiefly from lower settlements and incentive payouts, plus reduced inventory levels. We advanced our working capital management efforts in 2024, especially in optimizing inventories at Pharma and Crop Science. Net financial debt fell to EUR 32.6 billion by the close of 2024, thanks to the positive cash contribution and squarely in line with the guidance we gave at the Capital Markets Day. Worth noting is that we saw a substantial debt-increasing FX translation effect from the stronger U.S. dollar. Let's turn now to the 2025 outlook. I'd like to begin with the key drivers behind the year-over-year changes in core earnings per share. As we already flagged in November, the faster decline of high-margin Xarelto sales, together with the loss of the dicamba label and the Movento registration in Europe within Crop Science, will weigh on earnings year over year to a significant degree.
Wolfgang Nickl
executiveBeyond that, merit and inflation are factored into our guidance. On the upside, we anticipate gross contributions from greater volumes in corn and crop protection, plus our pharma launch assets. We also expect our Consumer Health business to get back to volume growth. In addition, we intend to deliver the next tranche of EUR 800 million in incremental savings on the way to our goal of roughly EUR 2 billion in total by the end of 2026. The core financial result and our core tax rate should stay broadly in line with last year's levels. Consequently, we expect core earnings per share of between EUR 4.50 and EUR 5 at constant currencies. All of our modeling assumptions are set out in the appendix to our presentation. Let's turn now to our outlook for all group KPIs for 2025. We anticipate net sales of between EUR 45 billion and EUR 47 billion, a gross range of -3% to +1% in currency and portfolio-adjusted terms. For EBITDA before special items, we anticipate EUR 9.5 billion-EUR 10 billion in 2025, a 1%-6% decline at constant currencies, driven mainly by the negative product mix effect from the accelerated Xarelto decline, as well as the loss of Movento and dicamba in Crop Science.
Wolfgang Nickl
executiveAs already noted, we expect core earnings per share to land in the range of EUR 4.50 to EUR 5 at constant currencies. For free cash flow, our outlook stands at EUR 1.5 billion to EUR 2.5 billion at constant currencies, and it takes into account the lower profitability we now expect year over year, along with higher severance payouts and short-term incentive payouts tied to the year 2024. Additional working capital reductions will partly offset these effects. Net financial debt is expected to fall to EUR 31 billion to EUR 32 billion at constant currencies. The proposed minimum dividend payout is included in our plans, as are minor M&A milestone payments, pension funding, and other items that consume free cash flow. The estimated foreign exchange impact, based on month-end December 2024 spot rates, appears in the last column of this slide. Let me also use this opportunity to summarize the key swing factors behind our 2025 guidance. My colleagues will of course provide more color on that later. For Pharma, the primary source of risk and opportunity within our guidance range concerns how quickly and how extensively Xarelto genericization unfolds. Our Crop Science outlook hinges on how channel inventory levels develop in the industry and on pricing pressure in Crop Protection, as well as on the degree of ag market recovery this year.
Wolfgang Nickl
executiveWhen it comes to Consumer Health, our guidance factors in the possibility of additional trade inventory pressure across retail markets. The guidance we have right now does not factor in any geopolitical uncertainty—especially regarding potential tariffs—nor does it factor in exchange rate fluctuations. Turning to our strategic priorities, I want to restate that we stay fully focused on and committed to bringing down debt, with the goal of gaining greater strategic flexibility and moving toward a single A category. You saw that focus on cash generation and targeted capital allocation last year. During 2024, our improvement initiatives brought the working capital to sales ratio down to 25%. As I said, we made progress particularly in inventories, but also in weighted average terms with suppliers. On CapEx, we need to distinguish between investments in property, plant and equipment, or PP&E, and intangible assets. Fixed assets as a percentage of net sales fell significantly to 3.5% last year, thanks to diligent assessment and reprioritization. The blue line in the bottom right chart reflects this. Total CapEx as a percent of sales rose slightly year on year. That came from intangible CapEx, including higher milestone payments and investments in business development and licensing, in line with our strategic priority of replenishing our Pharma pipeline.
Wolfgang Nickl
executiveLooking ahead to 2025, we anticipate a lower profit, though we'll push even harder on converting cash and keeping a close eye on CapEx. Let me give you a few examples. Last year our Pharma division kicked off a wide-ranging project aimed at bringing inventory levels down substantially. The effort centers on both supply and demand, and on the idea that cash-intensive launch products must be offset through optimizations elsewhere in the portfolio. In Crop Science, the team intends to deliver working capital improvements totaling more than EUR 1.5 billion by the close of 2029. Rodrigo will go into detail on that when he speaks, and in fact, I'm passing it to Rodrigo right now.
Rodrigo Santos
executiveThanks so much, Wolfgang. Good morning, and good afternoon to all of you. I appreciate you spending time with us as we go through the Crop Science 2024 full year results. Agriculture had a difficult year, and farmers did too — and we feel that as well. Market headwinds, regulatory hurdles, and competitive pressures all weighed on our performance and put our resilience to the test. Today I want to give you a clear picture of where we stand, the strategic steps we are taking, and why I remain confident in the future of our business. Against a challenging backdrop, 2024 sales were in line with the ag market, down 2%. This is cycling over a very strong 2023 performance in our core business. Our EBITDA margin landed at 19.4%, impacted by lower crop protection prices and inflationary cost increases, while partially offset by DSO improvements and reduced cost of goods sold. Let me highlight two facts on the glyphosate business. First, it represents the vast majority of the divisional price decline we saw this year and is strongly dilutive to our overall margin, contributing more than 200 basis points of headwinds. It's also important to understand that our performance differs across our business segments. So let me break down how we look to our portfolio.
Rodrigo Santos
executiveOn seeds and traits sales, we're holding steady in a market that has weakened. Corn sales fell 3%, driven by an area reduction stemming from drought and disease pressure in Latin America, along with somewhat lower volumes in North America. Growth in soy, in other seed, and in traits segments — vegetables, oilseeds, cotton — helped offset that impact, and in Crop Protection we saw a 4% decline that tracked the market, mirroring pricing pressure from generics, continued stocking, and reduced herbicide volumes tied to acreage decline. Glyphosate sales were down 6%, which reflects considerable market price pressure even as volumes recovered. Now let's turn our attention to 2025. We expect the market to recover slowly. We'll use this moment to shore up our foundation, and after that shift toward growth. Notwithstanding significant challenges, particularly on the regulatory front, our top-line growth outlook for the year should land in the range of -2% to +2%. On top of that, we expect an EBITDA margin in line with prior year levels, in the 18%-20% range. To achieve that, we'll implement measures that offset the headwinds. Seeds and traits should dip slightly in the U.S. because of regulatory headwinds arising from the dicamba label loss. We look for recovery in Latin America, while EMEA and APAC are projected to deliver double-digit growth.
Rodrigo Santos
executiveWe expect our core crop protection business to grow slightly, driven by more acres being planted with our products. That gain will be partly offset by ongoing pricing pressure and by the regulatory hit from the Movento registration expiring. As you'll recall, back in November we guided to a regulatory impact of roughly 200 to 300 basis points, affecting both the top and bottom line. On Glyphosate, we expect it to stay strong this year, with pricing pressure continuing through at least the first half. Against that backdrop — and including the highly dilutive effect of this part of the business that I mentioned earlier — we are changing our model so glyphosate runs as a separately managed business. Let me say a few words about the first quarter of 2025. We expect a significant share of the regulatory impact we told you about to show up in Q1. Beyond that, our strategic decision to consolidate the regional brands in the U.S. will move revenue recognition out of the first quarter and into the second quarter of this year, closer to when customers make their purchases. Consequently, for Q1 we expect sales to decline in the mid-single digits versus the first quarter of last year. As for the whole year, I can tell you demand is strong, corn acres are positioned to rebound, and we have confidence in our full year guidance.
Rodrigo Santos
executiveLet me turn now to the steps we're taking to make Crop Science stronger, so that Bayer and our customers are set up to succeed over the long term. We've put in place a comprehensive framework spanning 5 years, designed to bolster our resilience and unlock our full potential on both the bottom and the top line. During Q2, investors will be invited to a virtual session at which we'll share more detail on the path we intend to follow in order to sustain market leadership over the long term. Today I'd like to take you through several of the central measures within this framework, which rests on the progress we have already achieved in rolling out our new operating model. Everything we did last year was centered on the customer — setting up cross-functional teams and giving clear P&L responsibility. That foundation is what our 5-year framework builds upon, and it is structured in 3 phases. The first is to strengthen the foundation. The second is to capitalize on pipeline value in the core. And the third is to expand beyond the core. As we carry out the first 2 phases of this framework, we anticipate generating more than EUR 1 billion in margin improvement, over EUR 1.5 billion in additional cumulative cash from working capital improvements, and more than EUR 3.5 billion in incremental revenue driven by innovation before the decade is out. Execution of our 5-year framework is already under way, with the initial steps, our 4 key margin initiatives, and 1 cash initiative.
Rodrigo Santos
executiveReinforcing the base of the business is going to generate better margins throughout the value chain, putting more than EUR 1 billion onto the bottom line. Our work is concentrated on the product portfolio, research and development, product supply, go-to-market, digital, and enabling functions. We're also acting to boost cash productivity, with more than EUR 1 billion of additional cumulative cash by 2024. Working capital improvements will account for most of that. As an example, we'll keep optimizing where inventory stands by building end-to-end accountability spanning production, supply chain, and commercial. We've likewise reoriented our innovation pipeline, which leads the industry. Our attention has been sharpened around a clear midterm strategy spanning our three key platforms, and we're confident this delivers an additional EUR 3.5 billion of net sales by 2029 while letting us outpace both the market and our key competitors. In corn, farmers keep demonstrating confidence in our platform, which begins with our germplasm, and we'll push our number one position even further as we scale up Preceon Smart Corn, the next generation of biotech traits, plus further expansion into other markets such as European silage or traits in Africa. In soy, we have a clear route to our global position, beginning with the leading insect control in Latin America.
Rodrigo Santos
executiveAnd within the U.S., we anticipate winning back share behind our strong germplasm, focused go-to-market initiatives, and the 2027 introduction of Vyconic, the HT4 trait we've just branded. Moving to CP, we're tightening our focus by bringing R&D and commercial teams together around high-value opportunities, crops with high yields, and attractive markets. Our pipeline is positioned to produce blockbuster offerings such as the fungicide Iblon, the insecticide Plenexos, and the herbicide Icafolin. Past those core platforms, we're pursuing future growth avenues that will release additional value for regenerative ag systems — among them novel biofuel crops, biologics, and meaningful value arriving over the decade. As I noted earlier, we're confident our five-year framework sharpens the business as it stands today and sets the stage for market leadership across growth, profitability, and resilience in business steering. First, our aim is above-market top-line growth. That will be driven by the incremental EUR 3.5 billion in sales stemming from base innovation — our germplasm and crop protection lifecycle management — along with the new blockbuster launches we hold. Second, we're aiming for an EBITDA margin in the mid-20s by the close of the decade. We'll get there by generating average annual EBITDA margin expansion of 100 to 150 basis points.
Rodrigo Santos
executiveIn the early part of that window, we're looking to grow margins by making improvements throughout our value chain. In the later part, we expect margin gains to come more from the top line, as our major high-margin blockbusters start launching in 2027. It's worth noting that this ambition also covers our Glyphosate business, at around EUR 2.6 billion, which we expect will stay dilutive to our EBITDA margin. We'll manage that business along each leg of the triangle — growth, margin, and cash — with our new operating model at the center, so the organization stays focused on the right priorities. We're also making our organization more resilient and adaptable so we can handle macroeconomic and geopolitical uncertainties we can't control. To close, here's my takeaway: we're committed to decisive action, focused growth, margin expansion, and market leadership. Both in the Q&A and in more detail at our upcoming event, I look forward to engaging with you on our five-year framework, including an update on our pipeline advancements and insights into future growth opportunities. Thank you — with that, I'll hand it to Julio.
Julio Triana
executiveThanks, Rodrigo, and hi everybody. The past year brought plenty of peaks and valleys, with notable shifts in the market — economic uncertainty among them, plus changes in how retailers behave. We called out those uncertainties on our Q3 calls, and they played out just as we anticipated. Our teams managed to steer through them and hit the guidance we had revised, while also setting the groundwork for growth ahead. As you'll remember, back in November I laid out our goal of achieving a healthier balance across growth, volumes, and pricing. We're making moves to strengthen that, and what gives me confidence is that consumption — meaning how our products sold at the point of sale — stayed in step with market trends during the past year. That's a solid indicator of our strong standing and of consumers' trust in our brands. Digging into the figures a bit more, worldwide sales rose 1.9% versus the prior year. We achieved growth in almost every category, which helped counter a 12% drop in allergy and cold stemming from soft seasonal demand. Dermatology was up 10%, powered by robust demand for Bepanthen and for Canesten, plus innovations such as Kangwang in China. Digestive Health climbed 8%, helped by better supply and the U.S. launch of Iberogast. Pain & Cardio advanced 7%, while nutritionals rose 3%. On the profit side, our clean EBITDA margin held firm at 23.3%, matching last year.
Julio Triana
executiveClean EBITDA came in at approximately EUR 1.4 billion, a decline of 3% compared with the prior year, mainly reflecting currency impacts. Even with those headwinds, our margin held firm, and that's thanks to the efficiency programs that continue to deliver. Looking ahead, our attention is on the recalibrated strategy we refer to as Road to Billions. Built into that strategy is our aim to broaden growth driven by volume, especially where our top brands and attractive markets overlap. Three levers in particular have our focus. The first is execution of our brand growth model. This concerns the fundamentals of building brands. That means distinctive communications, seamless availability across physical and digital channels, strategic pricing, and science-led innovation. The second is shaping our portfolio. Key growth contributors will get priority while we simplify the portfolio. Our attention is on the top brand and country intersections, releasing resources for investment in the highest potential combinations while cutting complexity. The third is fostering an agile and empowered organization. With our new operating model, we can grow through rapid innovation and customer response and become more efficient through increased empowerment. So how does all of this translate into our outlook? For 2025, we anticipate the market normalizing, with diminished effects from pricing and a stable, attractive growth trajectory.
Julio Triana
executiveOur goal is sales growth of 2% to 5%, spread broadly across every region and category. The foundational work done in 2024 should, we believe, translate into a more balanced dynamic between volume and price in our results. Our operating model will bring speed and efficiency, which helps us offset lingering inflation effects. We expect a clean EBITDA margin of 23% to 24%, navigating cost efficiencies, investment in brands, and economic headwinds. Looking past 2025, our midterm ambition is clear. We aim to grow sustainably above the market, deliver profitability competitive in our industry, and generate consistent and robust cash flow. In conclusion, I am confident in our fundamentals. We have a bold vision, a dedicated team, and a strong portfolio. Together, we will reach billions of people with the most trusted solutions they need. With that, over to you, Stefan.
Stefan Oelrich
executiveThanks, Julio. Now turning to Pharma, where our division exceeded what we had promised and closed 2024 with net sales growth of 3.3% on a currency- and portfolio-adjusted basis. We also delivered a 26% EBITDA margin, landing at the upper end of our 2024 guidance for Pharma. Thanks to strong growth from our launch medicines Nubeqa and KERENDIA, at 78% and 74% respectively, we more than offset the substantial but well-flagged declines for Xarelto tied to patent expiries and generic at-risk launches. Eylea and our base business both turned in robust performance once again. Eylea's 5% xpa growth was supported by a successful launch of our Eylea 8 mg dose after its approval, along with last year's launch of the prefilled syringe. Looking at Bayer Pharma's regional performance, North America represented roughly 30% of divisional sales in 2024, lifted by double-digit growth in the final quarter. We were also pleased to see sales in China stabilizing following the many industry-wide market challenges we faced over recent years. FX headwinds in 2024 weighed heavily on both the division's top and bottom line, cutting EBITDA before special items by roughly EUR 0.5 billion versus the prior year.
Stefan Oelrich
executiveBeyond that, we observed a continuing unfavorable product mix shift, largely driven by lower Xarelto sales, whereas license fee-bearing sales for Nubeqa and Eylea increased. R&D costs declined compared with the prior year after the OCEANIC-AF trial was discontinued in Q4 2023, and by adjusting selling expenses for our mature products, we also more than offset greater launch investments. Conversely, 2024 brought normalized incentive provisions and reduced income from non-core asset disposals versus the prior year. Looking to 2025, we anticipate continued growth from our launch medicines Nubeqa and KERENDIA, with combined sales surpassing the EUR 2.5 billion threshold. We also expect our base business and the Eylea franchise to remain resilient. On the negative side, an expected acceleration in Xarelto's sales decline will pressure our top line, since we will face not only further patent expiries but also added risk from EU patent rulings and at-risk generic launches. Given the scale of our regional businesses and the fact that we are still early in the year, our scenario planning continues to cover a wide range of outcomes, with Xarelto sales declines in 2025 likely falling somewhere between EUR 1 billion and EUR 1.5 billion.
Stefan Oelrich
executiveAs the year goes on, we’ll be able to give you more detail and possibly tighten that range. That said, right now it is completely reflected in the guidance for our division, where we expect sales on a currency- and portfolio-adjusted basis to fall by 4% to 1%. The product mix shift that is still underway will keep putting pressure on our margin as well, though we anticipate that strict cost control and savings from our efficiency efforts will offset most of that. So for 2025, we’re expecting an EBITDA margin of 23% to 26% at constant currencies. On both the top and bottom lines, we expect the first half of this year to be stronger than the second half. Turning to our midterm ambition, we will keep executing our strategic agenda and drive top-line renewal and value growth from our pipeline while making use of our new operating model. As a reminder, division sales should stay roughly flat versus 2023 levels across the 2024 to 2026 period, which effectively limits how much the overall Xarelto loss of exclusivity affects our top line. Given the Xarelto genericization dynamics I described earlier, the division will hit a sales trough in either 2025 or 2026, and our next growth wave will follow no later than 2027, driven, of course, by Nubeqa and KERENDIA, along with our new launches of Beyonttra and Elinzanetant.
Stefan Oelrich
executiveThe anticipated data readout for Asundexian in secondary stroke prevention during this year's second half might offer one more potential growth opportunity in that window if those results come back positive. Through putting our new operating model in place, we've redirected resources toward the assets and regions holding the most promise. We've gone through a rigorous process of removing layers and cutting roles, along with processes and activities that aren't focused on the mission. In exchange, greater productivity and efficiency across our organization are already visible today. Ongoing strict cost management underpins this, so no later than 2028 we anticipate our EBITDA margin will expand. Lastly, our fresh innovation model—centered on generating value and breakthrough innovation—is building considerable momentum, as Bill laid out earlier, and we are strongly dedicated to rebuilding a pipeline of high quality and differentiation by boosting R&D productivity. I look forward to bringing all of you further updates as we progress. With that, I'll hand it back to you, Jost.
Jost Reinhard
executiveThanks a lot, Stefan. Thank you, everyone. We're going to start the Q&A portion now. Just a few quick housekeeping notes before we get going. If you've got a question, please raise your hand and follow the directions given in the chat. And per usual, so we can fit in as many people as possible, please keep it to two questions. First up in the queue are James Quigley with Goldman Sachs, followed by Richard Vosser with JPMorgan. James, you're first. Please go ahead.
James Quigley
analystThanks, Jost, and I appreciate you taking my questions. This is James Quigley from Goldman Sachs. I have two, please, on the Pharma business. First, for Asundexian phase III OCEANIC-STROKE, the readout should come later this year. Recruitment was recently completed on clinicaltrials.gov, and the primary completion is still expected in October this year. So can we safely assume a fertility analysis or an interim analysis has already been passed, and that the event rate is tracking as expected? In other words, we should still see the data before the end of the year. And how are you viewing the market potential here, given the competition, given Milvexian with a potentially broader label, and Novartis reentering this space with an antibody option? The second question is on Pharma margins. Stefan, your mid-term commentary implies that 2027 could be the trough year for margins as you balance Xarelto patent expiries against R&D investment. First, consensus has a trough of around 23.3% EBITDA margin. Would you call that broadly reasonable as a trough? And second, to what extent does this factor in potential late-stage business development deals that could bring additional R&D? Would any BD deal at the clinical stage need to compete with current programs for R&D, or have you already built some room in the budget for this?
James Quigley
analystThank you.
Stefan Oelrich
executiveThank you, James. Those are excellent questions. To begin with Asundexian, your assumptions strike me as sensible, and I won't push back on them. Our expectation is that top-line data from the trial will be completed and published during the second half. Naturally, reaching that point requires the corresponding event accrual, so I'd say we're at a stage where our confidence that this will happen is solid. Regarding its potential, as I've noted on many occasions, it will largely hinge on what ultimately unfolds in this marketplace with other products reading out later on and possibly in further indications as well. For the stroke prevention indication on its own, though — assuming always that our data read out positively — we would be the first and only product approved in that patient group. And for that type of indication alone, I could certainly envision blockbuster potential. On margins, we've stayed very consistent since Capital Markets Day, having guided toward the mid-20s range for margins in the midterm outlook. We stand by that guidance. We've consistently noted that this excludes the FX impact that accompanies it. So the figure you mention would also fall within that range, more or less, when you look at FX, at least across the last two years.
Stefan Oelrich
executiveSo I’d say that’s an acceptable model as well. But we’ll be providing guidance in time for 2027. I think doing that right at the start of 2025 is a bit early.
Jost Reinhard
executiveThank you, Stefan, and thank you, James. Moving on, we have Richard Vosser from JPMorgan. Rich, the floor is yours.
Richard Vosser
analystThanks, Jost. I have two questions, both about Crop. First, regarding dicamba and soybeans this year, can you discuss the ongoing efforts to bring dicamba back to market in 2026, what you're observing about changes in the soy market in 2025, and how much lost sales or royalty income you believe you can recover? My second question concerns Glyphosate and is somewhat related to tariffs, I suppose. You mentioned increased price pressure, or some price pressure, in the U.S. Given the tariffs we already know about on China, do you think that could actually alter some of the pricing dynamics for glyphosate there from Chinese supply and actually provide a positive pricing benefit in 2025? Obviously, other tariffs in Europe could hit your Crop Protection business, but that's just my thought. I'll stop there. Thanks very much.
Rodrigo Santos
executiveThank you so much, Richard. I’ll begin with a question about soybeans, all right? We’re still working with EPA down in the U.S., and over the last few months we’ve seen the Farmers Association really pressing to get a solution in place for them ahead of next season. So, as you mentioned, we feel confident about getting the new herbicide registered for next season. On how this year is shaping up, you asked a bit about soybeans. In the U.S. we’re seeing corn acreage grow to somewhere between 92 million and 94 million. That ought to mean a reduction in soybean area, but we’re confident about the new herbicide for next season. That matters, and it gives us benefits there for 2026. It’s less tied to the licensing you brought up, because some of the licenses we’re discussing here—the big companies—are moving over to the other platform. We have far more when it comes to our market investments and what we did this year, and that will definitely be a positive for 2026. On Glyphosate, yes, potentially you could see that, and it ties to the tariff discussions we’re having, depending on where things end up, and there’s still plenty of volatility.
Rodrigo Santos
executiveWe're discussing that on this call today. A lot still needs to be worked out, but if it ultimately means an effect on imports coming from China, that ought to help pricing for us here in the U.S. That should have flattened things out. As Wolfgang said, we don't have that factored into the plan, but it ought to be a positive for us.
Jost Reinhard
executiveThank you, Richard. Thank you, Rodrigo. Up next we have Steve Byrne of Bank of America and Jo Walton of UBS. Steve, go ahead, please. Steve, are you able to hear us? Would you unmute your line? All right, in that case perhaps we'll take Jo Walton from UBS first. Jo, please go ahead. Oops, and then maybe we'll try with Jo or Steve. If either of you could unmute and proceed, please do.
Steve Byrne
analystYeah, this is Steve. Sorry about that.
Jost Reinhard
executiveThat's fine. We can hear you now.
Steve Byrne
analystRodrigo wants to know how your short stature corn trials went in 2024. How did yields compare with similar genetics in similar geographies? And did you notice any greater weed pressure or fungal disease pressure, given that the crop is shorter and planted at higher density?
Rodrigo Santos
executiveHey Steve, appreciate the question. We're really excited about the progress. Not long ago, we had our 300 groundbreaker farmers together with us at a meeting. We keep hearing more and more about the 300 club. Essentially, that means growers hitting over 300 bushels per acre using a short stature corn. I believe you went to see one of them. Bill got to spend time with one of those farmers this year.
Bill Anderson
executiveI'll now hand things over to 350.
Rodrigo Santos
executive350? That one landed well. Steve, here's what we're seeing. Everything the data shows us so far—and we'll have far more of it over the coming years as we expand—we're broadening what farmers can do. With density use, with high density, we're observing better yields. That's precisely the tailored launch we're running on this. And full credit to the U.S. team's excellent work, especially with growers, giving the right density recommendation and variable seed rate. Each time we do that, we see yield go up. Another very interesting point: we're working with partners in the U.S., and they told us we're helping farmers seed. They're helping growers feed those plants further so those higher yields can be driven. We haven't seen any other results like what you mentioned regarding weed pressure or disease. We'll need to keep checking that as we move forward. But the excitement is real. I think not only do I focus a bit more on the U.S., but if you look at Italy and Spain, where we're also expanding on silage, the results we're seeing are really good.
Rodrigo Santos
executiveWe're pretty enthusiastic about that as it relates to what we've got planned going forward. Thanks.
Steve Byrne
analystPerhaps just one brief additional question regarding that.
Rodrigo Santos
executiveAbsolutely.
Steve Byrne
analystWhat's your view on where acreage might land in 2025? In other words, what's your expectation over the longer term at this point for Preceon, and is there anything new on the gene-edited version you're working on? Yeah.
Rodrigo Santos
executiveSteve, that's a really good question. With all the talk about U.S. tariffs, you're seeing that volatility in the market at the moment. In last week's USDA reports, depending on which one you look at, corn acreage came in somewhere between 92 million acres and as much as 94 million acres. That's clearly up compared with last year. We've also seen recent developments affecting canola. So that's part of the picture — it remains difficult to say where planted acres in the U.S. will ultimately end up, but that's what we're seeing. On Preceon, we're making progress with our germplasm and with the breeding version you're familiar with. We're also moving ahead with the biotech version that's on the way, and that will significantly broaden penetration for it. And lastly, we're doing work with gene editing too, which could deliver even more when it comes to expanding the market geographically, right? So the expansion for Preceon will mainly come about when we launch the biotech version. That's part of one of our blockbusters coming in 2027 and beyond.
Jost Reinhard
executiveGreat. Thanks. Let’s try once more with Jo Walton, who is still waiting in the queue. Jo, go ahead when you’re ready. It looks like the connection still isn’t working. Then we have Thibault Boutherin from Morgan Stanley and Florent Cespedes from Bernstein. Up next is Thibault — please go ahead.
Thibault Boutherin
analystYes, thanks. Thanks a lot. I have a couple of quick questions. First, on the timing for the SCOTUS review — could you give us a sense of the path ahead, in terms of what you expect and when the first case gets filed? When do you think the SCOTUS will respond on whether they take the case? And from that point, how long until the final ruling? Then my second question: do you expect any tail value for Xarelto in some ex-U.S. markets? In other words, are there markets where, say, the LoE arrives somewhat later? So should we model any tail value there? Thank you.
Bill Anderson
executiveYeah. Thanks, Thibault. So regarding when the Supreme Court might review the preemption issue, it's a bit complicated, since several cases could actually serve as the basis for an appeal to the Supreme Court. And each one of those is making its way through the lower appellate courts. What we do expect is that we'll file something this year that will let us get into the docket for the 2025 to 2026 Supreme Court docket, so to speak, which means a ruling would come either toward the end of this year or in — I think it's the first half of 2026. So watch this space. We should know more about that within, I would say, the next 90 to 120 days. Maybe the picture starts to become a little clearer. And then, Stefan, do you want to comment on Xarelto?
Stefan Oelrich
executiveYeah. So Thibault, similar to what happens with other brands once they’re past exclusivity, we expect there will still be a tail. I’m not going to give you an exact figure, but we’ll probably land this plane somewhere around EUR 1± billion.
Jost Reinhard
executiveGreat. Next up are Sachin Jain with Bank of America and Emily Field with Barclays.
Bill Anderson
executiveYou didn't mention Florent.
Jost Reinhard
executiveSachin, you’re up next. Oh, that’s right—yeah, Florent. My apologies for that. Florent is the next person in the queue. Florent, go ahead, please.
Florent Cespedes
analystGood afternoon, and thanks so much for taking my questions. I have two quick ones, both for Stefan. First, regarding your launches this year, Beyonttra and Elinzanetant, could you give us a bit of color on how you see the dynamics there — if there's, let's say, a possibility of a good surprise on that front? That's my first question. My second question: I attended your R&D day back in 2023 in Boston, and I'd like to know when we should start to see some visibility on some of these projects, or overall on your early phase pipeline, because, of course, we'd like to see the growth and the long-term contribution from this asset space.
Stefan Oelrich
executiveFlorent, thank you for those great questions—I like both of them. First, on this year: creating a genuine element of surprise is going to be tough, since I probably don't have much time left to surprise you when it comes to total sales for this year. That said, we may well be able to surprise on our uptake curve. I'm watching the U.S. launch uptake of the equivalent of Beyonttra closely, and I'm sure you are as well, and the early signs there are very positive. So of course we aim to repeat that and hopefully do even better. I know our European organization is absolutely pumped about the Beyonttra launch, especially in markets where we'll likely get relatively quick access, like Germany. I hope we can show you some data toward the end of the year on how well we're doing. For Elinzanetant this year, I doubt we'll have a big splash this year, but I think we're all noticing greater appreciation for non-hormonal treatments in this category for women seeking relief from hot flashes. From a data standpoint, we believe we have a more than competitive medicine at the starting line, plus our legacy.
Stefan Oelrich
executiveAnd if you consider that, acceptance for this kind of therapy is growing. We might be launching at exactly the right time as we enter the U.S. market during the second half, just after the summer break, I suppose. But honestly, Florent, your second question really resonated with me, because clearly we haven't discussed our early to mid-stage pipeline while guiding for 2025. And yes, at some point this year, we're looking at providing a more detailed update on it. But you saw that we've now also gotten RMAT designation for our second program in Parkinson's with AskBio, which is a gene therapy program. A lot of these programs are being accelerated significantly, and to borrow one of my favorite quotes, it's getting late early. I mean, a sales number for it isn't something we're going to give you, but I think launches are approaching. We'd always stated that by the end of the decade we want to mature our early pipeline. More and more proof points of that happening I see. On top of that, our PSMA-TAT, which looks good. On top of that, our early pipeline at Vividion, a very promising technology platform.
Stefan Oelrich
executiveOn top of that, we have some cardiovascular assets developed internally. The picture is beginning to improve considerably. You will no doubt have seen our presentation at JPMorgan in January, when we offered something of an early glimpse of this. Keep watching. More will come during this year.
Jost Reinhard
executiveThanks — that’s great.
Florent Cespedes
analystThanks a lot, Stefan.
Jost Reinhard
executiveGreat. So next up we have Sachin Jain with Bank of America and Emily Field with Barclays. Sachin, please go ahead.
Sachin Jain
analystHello there, and thanks for taking my questions. I have two, please. The first concerns litigation. I'm wondering whether you could comment on the ongoing PCB Erickson review, when you would expect a ruling, and if you could remind us what the debates are for the judge. Then, most importantly, how do you think that ruling would be applied across the broader PCB litigation complex? The second is a follow-on for Stefan on Asundexian, given that we're approaching phase III, if we may. A couple of years ago, I think the phase II in stroke was perceived as mixed. There are no trial design papers yet. So could you comment on how you reflect the learnings from phase II into phase III? And then I just wanted to follow on James' question about the futility analyses. I'm assuming you've been through some. Is there any commentary you can give us as to what you've learned from those? Thank you.
Bill Anderson
executiveYes. Thank you, Sachin. So regarding Erickson, the Supreme Court in Washington State has agreed to take up the appeal. And the issues at stake: one is that statute of repose question. The second concerns the quality of the expert evidence, which the appeals court discussed at considerable length and, I believe, described as junk science. And then there were also questions about whether Missouri law applies in Washington State, and specifically on whether punitive damages are allowed under the Constitution in Washington State. I believe punitive damages account for something like 80% of the total in that Sky Valley set of litigation. How the ruling would apply to the other cases that are being disputed will depend on how they rule on the four topics. So the impact on the other verdicts could be quite massive. We look forward to learning the outcome from the Washington State Supreme Court. On timing, we understand it could come as soon as May, June, but it also could be much longer. So it could even flow over into next year. So it's hard to say, but that's the best estimates we have. And then I'll let Stefan comment on the other questions.
Stefan Oelrich
executiveThank you, Sachin. Turning to asset indexing, I think we have clearly picked up several lessons from our phase II program. As you recall, there were three separate phase II programs across three distinct settings, along with AMA in stroke prevention and in atrial fibrillation. Looking back, with what we have learned, a substantial bleeding benefit has been evident across all three programs. Yet a signal or evidence of better efficacy outcomes appeared only in a subgroup of the stroke trial. That is precisely the population our current trial targets. As you know, we are comparing against placebo as the standard of care, and in hindsight that was among the key reasons we did not succeed in atrial fibrillation, since our comparator arm was extremely effective. So this situation is quite different. I think our trial has been designed around what phase II taught us. Now we must wait and see what the data show. My hope is that we can bring one more catalyst to a late-stage pipeline that already appears far more promising than it did a few years ago.
Jost Reinhard
executiveAlright, let’s go on to Emily from Barclays. Emily, you have the floor.
Emily Field
analystHello, and thank you for allowing me to ask a question. I actually have two. First, please excuse me for seeking a clarification that builds on what James and Sachin raised — was there a futility analysis conducted for OCEANIC-STROKE? My apologies if that was already covered in the earlier response; I just wanted confirmation on it. Regardless, here are my questions. The first concerns your consumer segment. Several of your peers in consumer have commented on inventory levels, pointing to destocking in the U.S. as well as some liquidity issues with distributors in APAC. I wanted to know whether any of those issues are showing up for you as we move into 2025, and whether you have any update on the cough, cold and flu dynamics. My second question is a bit more big-picture. I realize there have been plenty of questions on dicamba and the EPA, but perhaps we can step back for a moment. You mentioned at Q3, in a broader sense, a regulatory environment that is more onerous. We keep getting many questions about HHS and the commentary around GMOs and ultra-processed foods. On the other side, though, the wider administration's objectives appear to lean somewhat more toward deregulation. And with Lee Zeldin at EPA, I would imagine he would be someone more favorable to your crop business.
Emily Field
analystI'm just sort of curious how you're thinking about the next 4 years across the U.S. regulatory landscape for crop. Thanks.
Stefan Oelrich
executiveEmily, regarding Asundexian, we didn't pre-specify a futility analysis in the trial, but we have reason to feel good that this trial is not futile.
Julio Triana
executiveYes. Emily, thanks very much for that question. Regarding wholesalers and retail partners making inventory adjustments, we certainly observed a great deal of that. You may recall that we mentioned it in our reporting for the first half of 2024. You're absolutely right about that. It hasn't been limited to the U.S. — I'd say it's occurred throughout the world. Honestly, I believe everyone is keeping a close eye on cash. All of us are contending with inflation and similar pressures. As a result, everybody is acting quite carefully when it comes to cash allocations. We'll keep seeing that this year as well. We anticipate it's already been incorporated into our figures — not to the same degree in our business as what we encountered in 2024, but it will persist. Once more, globally, we observed it in the U.S. and China. We saw it in certain Asia-Pacific countries, and in Latin America too. Now, on your separate question regarding cold and flu season, for 2025 it's actually among the strongest seasons we've witnessed in a couple of decades. There have already been two spikes, with one occurring at the start of the year.
Julio Triana
executiveThe second one happened around mid-February, and naturally, that will pull down some of the consumption out there. During 2024, cough and cold performance was quite weak. Thanks, Emily.
Bill Anderson
executiveYes, and Emily, on those regulatory questions, I believe you're raising the same point. Yes, a lot of people ask about it. I know farmers are asking it too. And I think we have to wait and see for a bit. We have a huge interest in providing a nutritious food supply for the world. And that's a core part of our mission. And we do very rigorous safety testing on all our products. Crop protection products undergo very rigorous safety. There's a huge amount of information published on this. You can go on, I invite you, go on the FDA website. You can look up the pesticide monitoring programs, and you can see the data and the food sampling. And so I think what matters the most is that the facts are laid out and that we have a scientific discussion of the facts. And Bayer feels incredibly strong about our position on this. As long as there's a fact-based discussion, yeah, we're quite happy. And I think we can work with, yeah, we work with different administrations from all over the world. But because we have the solid science on our side, we come to the same conclusion.
Bill Anderson
executiveTake Glyphosate, for instance — every regulator around the world has essentially granted it that same kind of stamp of approval. That's genuinely what interests us. So our plan is to keep that going.
Jost Reinhard
executiveGood. Our upcoming questions are from Sebastian Bray at Berenberg and Christian Faitz at Kepler. Sebastian, the floor is yours.
Sebastian Bray
analystGood afternoon, and thanks for taking my questions. I have two, please. First, on dicamba: is there any signal yet as to when the EPA will actually respond? And how do you see the risk that the spraying criteria are so burdensome that the product keeps shedding market share? My second question concerns margin development in ag over a two-year horizon. It ties back to the 2029 targets that have been set to climb back up into the very high 20s on the EBITDA margin. But is that a hockey stick trajectory? Because I take it that in 2026, agricultural commodity pricing is somewhat of a guess, though Bayer will need to put resources in to win back market share in dicamba and could wind up using price as a lever to get there. Is it fair to view this more as a curve that steepens at the end of the process, in terms of the shapeline for margin improvement? Thank you.
Rodrigo Santos
executiveThank you, Sebastian. Let me take up both of those questions. First, regarding dicamba: we have been engaged with the EPA since last year, and we will keep adhering to their process. When we consider the various scenarios in front of us, we believe approval of the new herbicide will be in place for the coming season. That is partly what our current plans assume — that for the next season, for 2026, the new herbicide would be available to us. We also believe we have supplied all the technical data needed to support what the label for that herbicide ought to be. With that, we feel good about the recommendations we are making to the EPA, and we believe the technical data backs them up. We should be able to deliver another strong season in 2026 and gain a little momentum. And as I said, that sets up the transition for 2027. So in 2027, we are already bringing farmers Vyconic, the HT4 with the five modes of action. And with that 2027 launch, we see ourselves regaining share in soybean. That is genuinely a high expectation from the farmers.
Rodrigo Santos
executiveWe're launching the new brand at Commodity Classic. And you can see the anticipation around that new technology for it. On our margin, the mid-20s we provided here at the end of the decade consists of two components, correct? One is the innovation we're discussing, such as Vyconic or Preceon or the launches we have in crop protection. So that's one piece generating the 3.5. And that likely arrives more toward the end of the decade that you mentioned. But there are also the margin improvement measures we have, over EUR 1 billion that we communicated here, which should come more at the beginning of that period. So combining these two components is what we're driving toward the mid-20s EBITDA margin we have. It's a combination of growth through the innovation we have and the 10 blockbusters through the measures we're putting in place for margin expansion as well across the entire value chain, as I said, and that should be expected earlier in that period of time. Thank you.
Sebastian Bray
analystI appreciate that.
Jost Reinhard
executiveAlright, Christian, the floor is yours.
Christian Faitz
analystYes, thank you for taking my question. I hope I'm audible. There are two questions, please. First, something broader. I mean, Bayer carries a fairly sizable transactional exposure, with many products manufactured centrally and then shipped between regions. To what extent are you impacted by any tariffs, whether in agrochemicals, pharmaceuticals, or OTCs? Have you run any modeling on that? Second, you said you want to manage Glyphosate separately. Would that at some point also mean that you at Bayer no longer wish to manage it at all, that is, putting the Glyphosate business up for sale? Thanks.
Bill Anderson
executiveOkay, thank you, Christian. Regarding the tariff question — yes, we've done extensive modeling on this. And I'd say that in recent years, we've taken a fair number of steps to, yeah, shield our business from being exposed to shifts in trade conditions. So for instance, when it comes to the effect of tariffs on goods from China, Mexico, and Canada entering the U.S., the impact on us is very minimal. There simply isn't much flow in those directions for us. The majority of our products sold in the U.S. within Crop Science and Consumer Health are made in the U.S. The area where we'd have somewhat more exposure is probably Pharmaceuticals, since we have a considerable amount of production in the E.U. So if tariffs were imposed from the E.U. to the U.S., that's likely something we'd have to deal with a bit more. It's very hard to predict what the impact would be, because naturally it hinges on the duration of the patents — sorry, of the tariffs. Are they sticky? Is this part of a negotiation that gets resolved? And clearly, we have various levers we can pull when it comes to inventories and timing and such to try to minimize the impact.
Bill Anderson
executiveStill, yes, that's a matter we treat with real seriousness, and we're ready to take action on it.
Christian Faitz
analystThat's quite useful. Thank you.
Rodrigo Santos
executiveNow, regarding your question about Glyphosate, Christian — the choice we've made today reflects the new operating model we're running under right now, where we set up microenterprises, correct? And we've got product teams in place. Those teams carry full accountability for the entire P&L as well as the cash generation from that unit. Every function is engaged with that microenterprise to get the most out of the business. That's what today's decision amounts to. We're building this team whose objective is to maximize that particular operation. It's a different kind of business from the one driven by innovation. This one is more of a commodity operation, with different metrics that we apply to it, whereas the innovation side demands its own set of measures. So what I can tell you about the decision made today is this: it's a cross-functional microenterprise team focused on maximizing the P&L and the cash generation of that business, using metrics that differ from the ones we use on innovation. That's the essence of it. And naturally, as we'll keep discussing going forward, we'll be assessing every alternative available for the business — that's something we always do.
Christian Faitz
analystGood. Thank you. Thank you so much, both of you.
Jost Reinhard
executiveAlright, and there are three more people waiting. Since we're running late, could everyone stick to a single question each? Up first is Laurent Favre from BNP Paribas, followed by Joel Jackson from BMO, and after that Rajesh Kumar from HSBC. Laurent, go ahead.
Laurent Favre
analystGood afternoon. For the last question, on the litigation strategy with multiple fronts tied to state law and, I assume, the Missouri vote: I’m wondering if you could say when you expect clarity there. And could you tell us, of the 181,000 outstanding Glyphosate cases, how many are actually in Missouri? Thank you.
Bill Anderson
executiveYeah, Laurent, before anything else, I want to make one thing clear about that outstanding figure on the cases.
Stefan Oelrich
executiveSixty-seven thousand.
Bill Anderson
executiveThe figure now stands at 67,000. So I suspect what you have in mind might be a broader total that takes in cases already settled.
Laurent Favre
analystYeah. Yeah.
Bill Anderson
executiveAnd Missouri — that's a fairly high share, around 80%. But it isn't quite that straightforward, because, yes, where the person comes from also affects how the law applies. So for instance, if someone from Georgia files a suit in Missouri, the trial would take place in Missouri, yet there's a reference to Georgia law. So, yeah, just to give a bit of clarity on that point. We're working with farmers' groups throughout America on legislation at the U.S. Congress and then in a number of states, Missouri included. And the timing is somewhat hard to predict. It relates to the legislative calendars in each location. Most of the state legislatures, though, are front-loaded at the start of the year. So probably, by summer, we would have answers in most states about whether legislation would be possible in this legislative session. So hopefully that answers your question.
Laurent Favre
analystThanks.
Jost Reinhard
executiveAlright, Joel is up next. Go ahead, please.
Joel Jackson
analystHi there, can you hear me okay?
Jost Reinhard
executiveYes, Joel, we’re able to hear you.
Joel Jackson
analystApologies for that. This question might be for Bill. I was taken aback when you said today that Crop Science is now improving — sorry, that profitability at Crop Science is now a fifth focus area. And previously it wasn't one. Could you explain that? Why would your core businesses, with such strong growth potential, not have been a focus area? That terminology just leaves me a bit puzzled.
Bill Anderson
executiveSure, absolutely. I wouldn't dwell on it too much. The way I see it, we're constantly striving to boost profitability across every one of our businesses. What took place in the agriculture market — and especially in crop protection over the past 18 months — was a genuine price collapse. If you examine the crop protection market in 2020, 2021, and 2022, it was in fact pretty robust. During 2023, the first half was likewise fairly strong. Then, in the latter half of that year, conditions deteriorated markedly. So when we appeared at the capital markets event last year and stated, "Look, we have four focus areas," that came in a setting where the industry had already seen some unfavorable results in crop protection. But I think it wasn't clear whether, "Oh, is this a temporary phenomenon tied to inventory levels in Latin America?" You likely recall some of that discussion throughout the industry. Over the course of 2024, it became evident that, no, this was not a short-term phenomenon. This is a structural issue. And so we've said, "Hey, this has to be a major, major priority for us." That's why you hear us framing it that way.
Bill Anderson
executiveStefan is focused on the profit margins in Pharma, while Julio is handling profit margins in Consumer Health. That said, we feel a particular urgency here given some of the changes that might be needed to reach that point. So hopefully that's clear to you, Joel.
Jost Reinhard
executiveThanks. Rajesh, you're the final one in the queue, so please go ahead.
Rajesh Kumar
analystGood afternoon, and thank you for taking my question. I appreciate the margin targets you've laid out. Since growth is arguably a somewhat larger issue right now, how much of the cost savings you're producing might need to be plowed back into the business? And most importantly, when we consider pipeline investments—whether in pharma or elsewhere—how high a priority is that for you?
Bill Anderson
executiveI’d say, at a high level, we have a program — our Dynamic Shared Ownership program — and it produces cost savings. Those are the first effects you notice, because clearly when 10,000 positions go away, there is an immediate kind of cost impact that shows up in the cost center report that month. But what arrives soon afterward is speed. That is really where everyone on the Management Board is focused — basically, how do we make decision-making faster? So we’re seeing examples that are now too numerous to list, whether in Consumer Health, where we have, I don’t know, dozens of products that we thought would be launching over a two- to three-year timeframe and are instead getting launched in 12 to 18 months. I mean, we’re seeing this in how we responded to some demand softening on certain core pharma products in North America last year — one of our front-runners. They turned it around really fast. And wherever we go, Bayer employees tell us, “Wow, we are moving way faster on this than we ever did before.” We were just discussing this in Canada this morning — that we had a 70% reduction in management positions, but we ended up with an 18% increase in customer-facing roles.
Bill Anderson
executiveAnd it doesn't seem accidental to me that we've gained share in seeds, corn, soy, and crop protection. So we're aware — more than aware — that growth has to be driven, that we won't, that we won't reach greatness by cutting costs. But we believe our operating system gives us something that truly unlocks the full potential of every Bayer person, and that will fuel the top line while lowering costs. So that's the path we're on. I don't think we're viewing this through the lens of how much margin we'll need to reinvest. We have business development work underway in all three divisions, especially in Pharma and Crop Science. And I don't know whether you'd want to weigh in on that.
Rodrigo Santos
executiveIf I may put it this way, when you think about us as a top player in Crop Science, we're pushing the triangle that Wolfgang talks about a lot, that I talk about, and that all of us talk about. That triangle is essentially about how we deliver strong results on growth, on margin, and on cash. Those 3 elements can coexist, and we have to drive strong results. In Crop Science, over the last 4 years, our core business grew at a 5.3% CAGR. And the innovation growth we've been discussing comes with the pipeline and the 10 blockbusters. Yes, we're placing greater emphasis on expanding margin to drive that too. But we will drive growth, we will drive margin expansion, and a huge effort as well on cash conversion. So those 3 elements of the triangle matter to us, and we're confident we can lead with strong results across all 3. We're putting slightly more focus or emphasis here since it offers more information, but that's the objective we have.
Stefan Oelrich
executiveSure, I can expand on that point for Pharma. If you look at the past few years and how we've managed our P&L, it has really been a continual reallocation of line items, and we've achieved enormous savings thanks to the restructuring work we've done. To give you a few reference points on that: five years ago, when I started, R&D stood at 14% of sales. It's 18% today. So a great deal of the money we had been putting into sales and marketing has been moved into R&D. We've also redirected a lot of the money we've been saving on sales and marketing in Europe over to the U.S. in order to fund our launch efforts there. So I believe a good company will always look to reinvest part of what you might call the savings that you generate. And naturally, you'll also want to protect margin, particularly when growth isn't there. So it's always a healthy blend of those things.
Jost Reinhard
executiveThank you so much. That's really a fantastic way to wrap things up. So with that, we're bringing today's call to a close. We appreciate your questions, and we hope each of you has a wonderful day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Bayer Aktiengesellschaft transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Bayer Aktiengesellschaft earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Bayer Aktiengesellschaft or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.